Vol. 24/No. 15 | Oncology Live®

September 25, 2023

Although some community oncologists may think they can do little to abate the reimbursement reform forces that are affecting their practices, there are actions they can, and should, take to influence the success of their value-based care journey that may not be part of the fundamentals of their current practice.

September 23, 2023

The 18th Annual New York Lung Cancers Symposium, scheduled for November 11, 2023, as a live meeting in New York, New York, boasts an agenda that covers a broad range of modern clinical topics.

September 22, 2023

Circulating tumor DNA status at the time of postoperative minimal residual disease is a prognostic factor of recurrence for patients with radically resected stage II to IV colorectal cancer

September 20, 2023

As oncogene-driven therapies move into clinical practice, it is paramount that clinicians have the tools and understanding to integrate the latest evidence for the appropriate treatment of patients with lung cancer.

September 19, 2023

Over the past 10 years, data from studies including the TAILORx and RxPONDER studies have reshaped treatment standards for patients with hormone receptor–positive, HER2-negative breast cancer.

September 18, 2023

Although findings from the International Duration Evaluation of Adjuvant Therapy collaboration in 2018 failed to demonstrate the noninferiority of 3 months of adjuvant chemotherapy vs 6 months for patients with stage III colon cancer, clinically relevant data in subgroup analyses have influenced practice prescribing patterns, according to a retrospective analysis.

September 18, 2023

The development of novel next-generation hormonal agents is poised to change the landscape for patients with estrogen receptor-positive, HER2-negative breast cancer, offering additional oral solutions to lessen the burden of the invasive delivery of the standard of care and provide agents that are active against acquired variants.

September 06, 2023

The well-publicized severe shortage of vitally important generic antineoplastic agents has highlighted a serious misalignment in the existing market-based and regulatory environment that permitted such an extraordinary situation to develop without meaningful resolution.